SHPH Stock Overview
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shuttle Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.75 |
| 52 Week Low | US$0.35 |
| Beta | 0 |
| 1 Month Change | -13.39% |
| 3 Month Change | -7.62% |
| 1 Year Change | -77.04% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.99% |
Recent News & Updates
Shareholder Returns
| SHPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.6% | -2.5% | -3.2% |
| 1Y | -77.0% | -3.7% | 19.3% |
Return vs Industry: SHPH underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: SHPH underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| SHPH volatility | |
|---|---|
| SHPH Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SHPH's share price has been volatile over the past 3 months.
Volatility Over Time: SHPH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Anatoly Dritschilo | www.shuttlepharma.com |
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Shuttle Pharmaceuticals Holdings, Inc. Fundamentals Summary
| SHPH fundamental statistics | |
|---|---|
| Market cap | US$6.50m |
| Earnings (TTM) | -US$6.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs SHPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.59m |
| Earnings | -US$6.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.0% |
How did SHPH perform over the long term?
See historical performance and comparison